Related Experiment Videos

Association between achieving treatment goals for lipid-lowering and cardiovascular events in real clinical practice

Peter Lindgren1, Fredrik Borgström, Jan Stålhammar

  • 1Stockholm Health Economics, Stockholm, Sweden. peter.lindgren@healtheconomics.se

European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology
|December 2, 2005
PubMed

Insights

Achieving lipid-lowering treatment goals significantly reduces cardiovascular event risk by 24%. Ensuring patients reach these critical therapeutic targets is vital for preventing major cardiovascular events in high-risk individuals.

Area of Science:

  • Cardiology
  • Pharmacology
  • Public Health

Background:

  • Lipid-lowering agents effectively reduce cardiovascular morbidity and mortality.
  • A significant gap exists between high-risk patients needing treatment and those receiving it.
  • Many patients on lipid-lowering therapy do not achieve their treatment goals.

Purpose of the Study:

  • To investigate if failure to reach therapeutic goals with lipid-lowering agents increases cardiovascular event risk in real-world clinical practice.
  • To assess the impact of goal attainment on cardiovascular outcomes.

Main Methods:

  • Retrospective cohort study utilizing linked electronic medical records, Swedish national inpatient, and cause of death registries.
  • Inclusion of 4976 patients treated with lipid-lowering agents between 1993 and 2001.
  • Cox proportional hazards regression analysis to evaluate goal attainment and confounders.

Main Results:

  • Patients achieving treatment goals had a 24% lower risk of cardiovascular events (RR 0.76, 95% CI 0.60-0.96).
  • A substantial proportion of patients treated with lipid-lowering agents did not reach their therapeutic goals.
  • Failure to achieve goals was associated with increased cardiovascular event risk.

Conclusions:

  • Not reaching lipid-lowering treatment goals is associated with a higher risk of cardiovascular events.
  • Ensuring patients achieve therapeutic goals is crucial for cardiovascular risk reduction.
  • Clinical practice should focus on optimizing lipid-lowering therapy to meet treatment targets.
Abstract

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...